Market Access News | pharmaphorum

News

Joy as NICE changes tack on first NHS vitiligo treatment

NHS patients in England with vitiligo will soon be able to access Incyte's Opzelura, the first drug shown to reverse the skin-lightening disorder.

News

FDA maps new regulatory route for ultra-rare diseases

The FDA has sketched out its 'plausible mechanism' regulatory pathway for individualised therapies that treat ultra-rare diseases.

News

FDA clears first all-oral combo for first-line CLL treatment

AstraZeneca's Calquence and AbbVie/Roche's Venclexta have become the first all-oral, fixed-duration regimen for newly-diagnosed CLL.

News

What next for pharma as SCOTUS strikes down Trump tariffs?

The centrepiece of President Trump's economic strategy has been shattered after the Supreme Court ruled his sweeping tariffs are illegal.

News

FDA starts review of Regeneron's drug for rare disease FOP

Can Regeneron's drug for ultra-rare bone disease FOP pick up the baton from Ipsen's Sohonos, whose growth has stalled?

News

Woman on crutches, left-hand side of her body, face not revealed

UK firm steps in to ease medicine supply crisis in NHS

Amid reports that a shortage of bone cement in the UK is leading to delayed orthopaedic surgeries, Biocomposites has brought forward a product launch.

Joy as NICE changes tack on first NHS vitiligo treatment

FDA maps new regulatory route for ultra-rare diseases

FDA clears first all-oral combo for first-line CLL treatment

What next for pharma as SCOTUS strikes down Trump tariffs?

FDA starts review of Regeneron's drug for rare disease FOP

UK firm steps in to ease medicine supply crisis in NHS

Recordati gets €10.9bn takeover bid from private equity firm

Using AI-driven synthetic personas to take your insights fur...

News

Editor's Picks